Search

everythinglearnresearchcommunity

for

Search:↓

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Most patients experienced significant but reversible hair loss during treatment.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.

The treatment is safe and shows promise for metastatic breast cancer.

Taxane chemotherapy can cause permanent hair loss by damaging hair follicles and altering their DNA.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

MK-5108 is safe and shows potential against tumors, especially alone.

About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Ki-67 levels do not predict treatment response in triple-negative breast cancer.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.